TYSABRI Lifts Biogen (BIIB) to Q4 Beat; FY12 Outlook is Muted
Tweet Send to a FriendGet Alerts BIIB Hot Sheet
Price: $235.24 +1.13%
EPS Growth %: +40.7%
Financial Fact:
Other income (expense), net: -14.29M
Today's EPS Names:
ANF, DXLG, FL, More
EPS Growth %: +40.7%
Financial Fact:
Other income (expense), net: -14.29M
Today's EPS Names:
ANF, DXLG, FL, More
Trade BIIB Now!
Shares of Biogen Idec, Inc. (Nasdaq: BIIB) are trading higher Tuesday following strong fourth-quarter numbers but light guidance.
Fourth-quarter revenue rose 8.8 percent from $1.22 billion in the same period last year to $1.33 billion.
Net income increased 25 percent to $300.24 million, or $1.22 per diluted share. Adjusted for certain one-time expenses like stock options and asset amortization, net income was $1.51 per share in the quarter, beating views calling for earnings of $1.49 per share.
Global in-market sales of TYSABRI in the fourth quarter of 2011 rose 14 percent to $380 million. The total was comprised of $196 million in U.S. sales and $183 million in sales outside the U.S.
Biogen sees fiscal 2012 non-GAAP earnings of $6.10 to $6.20 per share, versus the consensus of $6.32.
Biogen shares are up 1.4 percent early Tuesday.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Fourth-quarter revenue rose 8.8 percent from $1.22 billion in the same period last year to $1.33 billion.
Net income increased 25 percent to $300.24 million, or $1.22 per diluted share. Adjusted for certain one-time expenses like stock options and asset amortization, net income was $1.51 per share in the quarter, beating views calling for earnings of $1.49 per share.
Global in-market sales of TYSABRI in the fourth quarter of 2011 rose 14 percent to $380 million. The total was comprised of $196 million in U.S. sales and $183 million in sales outside the U.S.
Biogen sees fiscal 2012 non-GAAP earnings of $6.10 to $6.20 per share, versus the consensus of $6.32.
Biogen shares are up 1.4 percent early Tuesday.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Abercrombie & Fitch Co. (ANF) Misses Q1 EPS by 4c; Guides FY Below Views
- Aeropostale, Inc. (ARO) Tops Q1 EPS by 1c; Guide for Wide Q2 Loss
- Childrens Place (PLCE) Tops Q1 EPS by 22c; Boosts Outlook
Create E-mail Alert Related Categories
Corporate News, EarningsRelated Entities
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
